HSD3B1 mediated anti-androgen resistance in prostate cancer requires specific androgen precursors

被引：0
|
作者：
Armstrong, Cameron M. [1 ]
Liu, Chengfei [1 ]
Lou, Wei [1 ]
Lombard, Alan P. [1 ]
Evans, Christopher [1 ]
Gao, Allen C. [1 ]
机构：
[1] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-3030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3030
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer
    Hearn, Jason W. D.
    Xie, Wanling
    Nakabayashi, Mari
    Almassi, Nima
    Reichard, Chad A.
    Pomerantz, Mark
    Kantoff, Philip W.
    Sharifi, Nima
    JAMA ONCOLOGY, 2018, 4 (04) : 558 - 562
  • [42] Third generation anti-androgen therapy of advanced prostate cancer
    Ohlmann, C. -H.
    Kamradt, J.
    Stoeckle, M.
    UROLOGE, 2012, 51 (04): : 522 - 526
  • [43] Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade
    Momozono, Hiroyuki
    Miyake, Hideaki
    Tei, Hiromoto
    Harada, Ken-Ichi
    Fujisawa, Masato
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (05) : 839 - 844
  • [44] Prevalence of osteoporosis in patients with prostate cancer on anti-androgen therapy
    Senan Sanz, M. R.
    Haro Iniesta, L.
    Riel Cabrera, R.
    Olive Ferre, F. X.
    Biel Arrufat, A.
    Matinero Romero, E.
    SWISS MEDICAL WEEKLY, 2009, 139 (33-34) : 151S - 151S
  • [45] Intermittent anti-androgen monotherapy: a possible treatment for androgen receptor-overexpressing prostate cancer
    Oliver, Tim
    Berney, Dan
    Shaw, Greg
    CANCER RESEARCH, 2015, 75
  • [46] Quantitative proteomic analysis of androgen & anti-androgen responses in the LNCaP prostate cancer cell line
    Rowland, JG
    Simon, JW
    Slabas, AR
    Robson, CN
    Leung, HY
    BRITISH JOURNAL OF CANCER, 2004, 91 : S38 - S38
  • [47] Independent validation of missense polymorphism in HSD3B1 in Japanese men treated with primary androgen-deprivation therapy for metastatic prostate cancer
    Shiota, Masaki
    Fujimoto, Naohiro
    Imada, Kenjiro
    Kashiwagi, Eiji
    Takeuchi, Ario
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Kajioka, Shunichi
    Uchiumi, Takeshi
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 352 - 352
  • [48] The effect on prostate volume of anti-androgen versus total androgen blockade in prostate cancer patients - a randomized study
    Majumder, K.
    Brandberg, Y.
    Johansson, H.
    Castellanos, E.
    Nilsson, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S485 - S485
  • [49] TET3 is expressed in prostate cancer tumor-associated macrophages and is associated with anti-androgen resistance
    Wei, Qiu-ju
    Liang, Hai-qi
    Liang, Yao-wen
    Huang, Zu-xin
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 1712 - 1727
  • [50] HSD3B1 genotype and abiraterone metabolism in patients with prostate cancer
    Alyamani, Mohammad
    Emamekhoo, Hamid
    Park, Sunho
    Taylor, Jennifer
    Almassi, Nima
    Upadhyay, Sunil
    Tyler, Allison
    Berk, Michael P.
    Hwang, Tae Hyun
    Grivas, Petros
    Rini, Brian
    Garcia, Jorge
    Auchus, Richard J.
    Sharifi, Nima
    CANCER RESEARCH, 2018, 78 (13)
12345